Prevalence of excessive daytime sleepiness (EDS) and its association with quality of life in patients with obstructive sleep apnea (OSA): data from a sleep-center in Shenzhen, a single-center cross-sectional study
Abstract
Background: Excessive daytime sleepiness (EDS) is considered to be one of the main clinical manifestations of obstructive sleep apnea (OSA) and is a treatment target for patients with OSA. The prevalence of EDS in patients with OSA remains unclear and there is a lack of studies on the associations of EDS with quality of life among patients with OSA in China. This study aimed to evaluate the prevalence of EDS and its association with quality of life in patients with OSA in Shenzhen, China. Methods: The cross-sectional study included patients diagnosed with OSA [apnea-hypopnea index (AHI) ≥5] at Shenzhen People's Hospital in China between May 21, 2023 and November 30, 2023. Differences in demographics, comorbidities, treatment, functional outcomes, and quality of life (measured using electronic questionnaires) in patients with and without EDS [Epworth Sleepiness Scale (ESS) ≥ and <10] were evaluated, as well as the prevalence of EDS, and its correlation using correlation analysis and logistic regression models. Results: A total of 334 patients with OSA were included, 84.7% were male, with an average age of 38.1 years, and 31.14% had EDS. Patients with EDS in OSA had worse functional status [Functional Outcomes of Sleep Questionnaire Short Version (FOSQ-10) (P<0.001)], more work impairment {World Health Organization Quality of Life-Brief (WHOQOL-BREF) [physical domain (P<0.001); psychological domain (P=0.01); social domain (P=0.009)]}, poor quality of life and general health…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 334 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.